No conflict of interest was declared.
The CADEUS study: methods and logistics†
Article first published online: 23 NOV 2006
Copyright © 2006 John Wiley & Sons, Ltd.
Pharmacoepidemiology and Drug Safety
Volume 16, Issue 5, pages 571–580, May 2007
How to Cite
Depont, F., Fourrier, A., Merlière, Y., Droz, C., Amouretti, M., Bégaud, B., Bénichou, J., Moride, Y., Blin, P. and Moore, N. (2007), The CADEUS study: methods and logistics. Pharmacoepidem. Drug Safe., 16: 571–580. doi: 10.1002/pds.1348
- Issue published online: 1 MAY 2007
- Article first published online: 23 NOV 2006
- Manuscript Accepted: 4 OCT 2006
- Manuscript Revised: 3 OCT 2006
- Manuscript Received: 30 MAY 2006
- Pfizer Inc.
- Merck and Co.
- drug utilization;
- healthcare systems;
- response rate;
- cox-2 inhibitor;
- non-steroidal anti-inflammatory drugs
At the request of the French Health authorities, a study called CADEUS (COX-2 inhibitors and NSAIDs: description of users) aimed to describe the users of cyclo-oxygenase (COX)-2 inhibitors and traditional non-selective non-steroidal anti-inflammatory drugs (tNSAIDs). We report here the methodology, logistics and study design performances.
CADEUS is a cohort study designed to include 40 000 patients randomly sampled monthly in the French National Healthcare Insurance database, who received at least one dispensation of celecoxib, rofecoxib or tNSAIDs (1:1:2), from September 2003 to August 2004. Patients and prescribers were asked to fill a questionnaire on indication, medical history, risk factors and hospitalizations since drug acquisition. There was no reminder. For each respondent, healthcare resources used for the 6 months before and after inclusion were extracted from the database. Response rate, response delay, responders and non-responders characteristics were assessed.
Of the 222 879 patients and their prescribers contacted, 20.8% patients and 32.6% prescribers responded. Median response delay was 16 days for patients and 17 days for physicians. Factors associated with patient response were age, cohort, type of prescriber and period of inclusion.
This is the first study of this design in France, combining data from a claims database and direct patient and prescriber questionnaires. Copyright © 2006 John Wiley & Sons, Ltd.